-  INCLUSION CRITERIA:

               1. Measurable metastatic or refractory/recurrent HPV-16+ cancer (determined by in
                  situ hybridization (ISH) or a polymerase chain reaction (PCR)-based test).

               2. Patients must be HLA-A*02 by low resolution typing, and HLA-A*02:01 by one of the
                  high resolution type results.

               3. All patients must have received prior first line standard therapy or declined
                  standard therapy.

               4. Patients with three or fewer brain metastases that have been treated with surgery
                  or stereotactic radiosurgery are eligible. Lesions that have been treated with
                  stereotactic radiosurgery must be clinically stable for one month before protocol
                  treatment. Patients with surgically resected brain metastases are eligible.

               5. Greater than or equal to 18 years of age.

               6. Able to understand and sign the Informed Consent Document.

               7. Clinical performance status of ECOG 0 or 1.

               8. Patients of both genders must be willing to practice birth control from the time
                  of enrollment on this study up to four months after treatment. Patients must be
                  willing to undergo testing for HPV-16 prior to becoming pregnant after this
                  period.

               9. Women of childbearing potential must have a negative pregnancy test because of
                  the potentially dangerous effects of the treatment on the fetus. Women of
                  childbearing potential are defined as all women except women who are
                  postmenopausal or who have had a hysterectomy. Postmenopausal will be defined as
                  women over the age of 55 who have not had a menstrual period in at least one
                  year. Because there is a potential risk for adverse events in nursing infants
                  secondary to treatment of the mother with E7 TCR transduced PBL, breastfeeding
                  should be discontinued if the mother is treated with E7 TCR transduced PBL. These
                  potential risks may also apply to other agents used in this study.

              10. Serology:

          -  Seronegative for HIV antibody. (The experimental treatment being evaluated in this
             protocol depends on an intact immune system. Patients who are HIV seropositive can
             have decreased immune-competence and thus are less responsive to the experimental
             treatment and more susceptible to its toxicities.)

          -  Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If
             hepatitis C antibody test is positive, then the patient must be tested for the
             presence of antigen by RT-PCR and be HCV RNA negative.

             a. Hematology:

          -  Absolute neutrophil count greater than 1000/mm^3 without the support of

        filgrastim.

          -  WBC greater than or equal to 3000/mm^3

          -  Platelet count greater than or equal to 100,000/mm^3

          -  Hemoglobin > 8.0 g/dL

             b. Chemistry:

          -  Serum ALT/AST less than or equal to 2.5 times the upper limit of normal

          -  Calculated creatinine clearance (CCr) greater than or equal to 50 mL/min/1.73^2 using
             the Cockcroft-Gault equation

          -  Total bilirubin less than or equal to 1.5 mg/dL, except in patients with Gilbert's
             Syndrome who must have a total bilirubin less than 3.0 mg/dL

             c. More than four weeks must have elapsed since any prior systemic therapy at the time
             the patient receives the E7 TCR cells.

        Note: Patients may have undergone minor surgical procedures within the past three weeks, as
        long as all toxicities have recovered to Grade 1 or less.

        EXCLUSION CRITERIA:

          1. Active systemic infections (for e.g.: requiring anti-infective treatment), coagulation
             disorders or other active major medical illnesses of the cardiovascular, respiratory
             or immune system, as evidenced by a positive stress thallium or comparable test,
             myocardial infarction, cardiac arrhythmias, severe obstructive or restrictive
             pulmonary disease. Patients with abnormal pulmonary function tests but stable
             obstructive or restrictive pulmonary disease may be eligible.

          2. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
             Disease).

          3. Concurrent opportunistic infections (The experimental treatment being evaluated in
             this protocol depends on an intact immune system. Patients who have decreased immune
             competence may be less responsive to the experimental treatment and more susceptible
             to its toxicities).

          4. Patients with autoimmune diseases such as Crohn s disease, ulcerative colitis,
             rheumatoid arthritis, autoimmune hepatitis or pancreatitis, and systemic lupus
             erythematosus. Hypothyroidism, vitiligo and other minor autoimmune disorders are not
             exclusionary.

          5. Patients on immunosuppressive drugs including corticosteroids. With the exception of:
             intranasal, inhaled, topical steroids, or local steroid injection (e.g.,
             intra-articular injection)

             -Systemic corticosteroids at physiologic doses 10 mg/day of prednisone or equivalent;

             or,

             -Steroids as premedication for hypersensitivity reactions (e.g., CT scan
             premedication)

          6. History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine
             or aldesleukin.

          7. Patients with a history of coronary revascularization or ischemic symptoms unless
             patient has a normal cardiac stress test.

          8. Documented LVEF of less than or equal to 45% tested. The following patients will
             undergo cardiac evaluations

               1. Clinically significant atrial and/or ventricular arrhythmias including but not
                  limited to: atrial fibrillation, ventricular tachycardia, second or third degree
                  heart block or

               2. Age greater than or equal to 50 years old

          9. Subjects with baseline screening pulse oxygen level of < 95% on room air will not be
             eligible. If the underlying cause of hypoxia improves, then they may be reevaluated